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Abstract
Background: The Canola Oil Multicenter Intervention Trial (COMIT) was a randomized controlled crossover study
designed to evaluate the effects of five diets that provided different oils and/or oil blends on cardiovascular disease
(CVD) risk factors in individuals with abdominal obesity. The present objective is to report preliminary findings on
plasma fatty acid profiles in volunteers with abdominal obesity, following the consumption of diets enriched with
n-3, n-6 and n-9 fatty acids.
Methods: COMIT was conducted at three clinical sites, Winnipeg, Manitoba, Canada, Québec City, Québec, Canada
and University Park, Pennsylvania, United States. Inclusion criteria were at least one of the followings: waist
circumference (≥90 cm for males and ≥84 cm for females), and at least one other criterion: triglycerides ≥1.7 mmol/L,
high density lipoprotein cholesterol <1 mmol/L (males) or <1.3 mmol/L (females), blood pressure ≥130 mmHg
(systolic) and/or ≥85 mmHg (diastolic), and glucose ≥5.5 mmol/L. Weight-maintaining diets that included shakes with
one of the dietary oil blends were provided during each of the five 30-day dietary phases. Dietary phases were
separated by four-week washout periods. Treatment oils were canola oil, high oleic canola oil, high oleic canola
oil enriched with docosahexaenoic acid (DHA), flax oil and safflower oil blend, and corn oil and safflower oil
blend. A per protocol approach with a mixed model analysis was decided to be appropriate for data analysis.
Results: One hundred and seventy volunteers were randomized and 130 completed the study with a dropout
rate of 23.5%. The mean plasma total DHA concentrations, which were analyzed among all participants as a
measure of adherence, increased by more than 100% in the DHA-enriched phase, compared to other phases,
demonstrating excellent dietary adherence.
Conclusions: Recruitment and retention strategies were effective in achieving a sufficient number of participants who
completed the study protocol to enable sufficient statistical power to resolve small differences in outcome measures. It
is expected that the study will generate important data thereby enhancing our understanding of the effects of n-3, n-6,
and n-9 fatty acid-containing oils on CVD risks.
Trial registration: ClinicalTrials.gov NCT01351012.
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It is well established that decreasing dietary saturated
fatty acids (SFA) reduces the risk of cardiovascular dis-
ease (CVD) [1]. Current dietary recommendations advise
that unsaturated fatty acids should replace SFA with
little guidance provided about the precise amounts that
should be substituted [2]. Epidemiological evidence
indicates various fatty acids classes including n-9 mono-
unsaturated (MUFA), n-3 and n-6 polyunsaturated fatty
acids (PUFA) as replacements for SFA with more health
benefits [3-8]. Despite the large body of research evaluat-
ing the effects of different fatty acid classes, studies that
systematically and simultaneously compare multiple fatty
acid classes have not been conducted. Moreover, a need
exists to evaluate additional biomarkers, beyond blood
lipids and/or lipoproteins, that better estimate risk of
clinical outcomes [9], and to achieve sufficiently large
sample sizes in order to resolve modest differences and
high variability in endpoint measurements. Additionally,
significant knowledge gaps remain in our understanding
of the effects of, and mechanisms underpinning the action
of, the various fatty acid classes on risk factors for chronic
diseases.
One such controversy is the debate surrounding α-
linolenic acid (ALA). Whether its effects are dependent
on its conversion to longer chain n-3 fatty acids [10-12]
needs to be better substantiated. The relative efficacy of
different classes of PUFA, specifically linoleic acid (LA)
[13], ALA and docosahexaenoic acid (DHA), in modulat-
ing inflammatory processes and endothelial function also
remains to be elucidated [14,15]. The reported undesirable
effects of LA [16] are of particular concern. A direct
comparison of dietary n-6 with n-3 fatty acids on in-
flammatory biomarkers and endothelial function would
also be helpful in clarifying these issues. Since inflam-
mation directly impacts endothelial function and the
progression of atherosclerosis [17,18], endothelial function
measurements would serve as useful biomarkers of CVD
risk.
Abdominal obesity and insulin resistance are criteria
for metabolic syndrome [19,20]. Dietary fat has been
implicated in the pathogenesis of this syndrome via ectopic
adipose tissue deposition [21,22]. Different classes of fatty
acids appear to have different effects on body fat accretion
[23-26]. Consequently, a need also exists to evaluate the
effects of various fatty acid classes on body composition
and body fat distribution.
Based on the above rationale, a multicenter randomized
clinical trial was designed to evaluate the biological effects
of conventional canola oil, high oleic canola oil, DHA-
enriched high oleic canola oil, a blend of flax oil with
safflower oil, and a blend of corn oil and safflower oil.
The contrast selected allowed for comparisons of the
effects of oils rich in n-9 versus n-3 and n-6 oil blends.
Circulating lipids and/or lipoproteins, inflammatory bio-
markers, endothelial function and body composition were
evaluated after each dietary treatment period. Addition-
ally, mechanistic assessments including reverse cholesterol
transport, stable isotope fatty acid conversion, and fatty
acid desaturase genetic variation analysis were also carried
out. Consequently, the purpose of this study was to
comprehensively investigate the effects of major fatty
acid classes on biomarkers of chronic disease at a
mechanistic level. This paper describes the protocol and
subject recruitment experience for the COMIT study and
presents plasma fatty acid data.
Methods
Study design
COMIT was designed as a five-phase randomized con-
trolled double-blind crossover clinical trial. One-hundred
and seventy subjects (n=95 females) aged 18 years or older
were selected with at least one metabolic syndrome clinical
criterion. Participants were recruited at two participating
centers in Canada, including the Richardson Centre for
Functional Foods and Nutraceuticals (RCFFN) at the
University of Manitoba in Winnipeg (n=69), and the
Institute on Nutrition and Functional Foods (INAF) at
L a v a lU n i v e r s i t yi nQ u é b e cC i t y( n=5 8 ) ,a sw e l la so n e
clinical institution in the United States: the Depart-
ments of Nutritional Sciences and Biobehavioral Health,
Pennsylvania State University, University Park (n=43). The
Risk Factor Modification Centre (RFMC) at St. Michael’s
Hospital in Toronto, Canada participated in the sample
analyses.
Study recruitment and retention
Recruitment was conducted using radio and newspaper
advertisements, direct mailings, community meetings, and
advertised information sessions as depicted in Table 1. On
first contact, volunteers completed a questionnaire to
determine their eligibility for the study. Qualifying par-
ticipants were instructed to provide a fasting blood sample
at their convenience. Eligible participants were selected
based on the inclusion criteria and exclusion criteria de-
scribed below. The flow of participants from initial contact
to completion is given in Figure 1.
At RCFFN in Winnipeg, a social program for study
participants termed ‘Club Richardson’ was initiated for
the purpose of fostering interaction and cooperation among
participants to enhance their retention and compliance.
Nutrition-related forums and outings were conducted, and
tickets to hockey and soccer games were provided. Specific
events were conducted to coincide with celebrations such
as Christmas. Wine and cheese events were also held dur-
ing the washout periods. Cards and flowers were gifted to
coincide with birthdays. Similar retention strategies were
used at the other two clinical centers. Personal interaction
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ticipants at all centers.
Inclusion criteria
Initially, discussions about the eligibility criteria of the
study were based on the following three parameters; 22
to 32 kg/m
2 body mass index (BMI), plasma triglycer-
ide >1.7 mmol/L, and waist to hip ratio of >0.85. When
the protocol was finalized, it was decided that focus should
be placed on waist circumference as the primary inclusion
criterion because of the relationship between visceral fat
and endothelial function [27]. At the beginning of the
study, the Adult Treatment Panel III (ATP III) metabolic
syndrome criteria for waist circumference (>102 cm for
men and >88 cm for women) were followed [28]. As the
trial progressed, the International Diabetes Federation
(IDF) metabolic syndrome criteria for waist circumference
(≥94 cm for men and ≥80 cm for women) were adopted
[29] to identify individuals in the initial stages of abdominal
obesity who might benefit from dietary intervention. This
change occurred at the same time in all centers and did not
Table 1 Recruitment strategies employed at participating
clinical sites
Clinical sites Recruitment tools
Winnipeg (Manitoba, Canada) Direct mail outs to neighborhoods
in the City of Winnipeg
University of Manitoba email system
Radio advertisements
Recruitment seminars at community
centers at various localities
University of Manitoba bulletin boards
Québec City (Québec, Canada) Institute of Nutrition and Functional
Foods (INAF) mailing list
Laval University email system
Newspaper advertisements
University Park (Pennsylvania,
United States)
Pennsylvania State University email
Flyers
Local newspaper advertisements
Television advertisements
Figure 1 Flow of participants in the COMIT study. The participant flow through each step of the COMIT recruitment, screening and study
protocol process. RCFFN, Richardson Centre for Functional Foods and Nutraceuticals. INAF, Institute on Nutrition and Functional Foods; PSU,
Pennsylvania State University.
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ence cutoff values were lowered. Other inclusion criteria
were triglyceride level (TG) ≥1.7 mmol/L, high density lipo-
protein cholesterol level (HDL) <1 mmol/L (males) or <1.3
mmol/L (females), blood pressure ≥130 mmHg (systolic)
and/or ≥85 mmHg (diastolic) and glucose level ≥5.5
mmol/L. Participants were required to meet at least the
waist criterion or any one of the other inclusion criteria
in order to be eligible.
Exclusion criteria
Individuals with thyroid disease (unless controlled by medi-
cation), diabetes mellitus, kidney disease, liver disease,
current smokers, or those consuming more than two
alcoholic drinks per week, were excluded from the
study. Individuals taking medications known to affect
lipid metabolism or endothelial function (including
aspirin or other non-steroidal anti-inflammatory drugs),
cholestyramine, colestipol, niacin, clofibrate, gemfibrozil,
probucol, or 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA)
reductase inhibitors were excluded. In addition, individ-
uals were not allowed to participate if they were unwilling
to stop taking any supplements at least two-weeks
prior to the study. Creatinine, serum glutamate pyruvate
transaminase (SGPT), serum glutamic oxaloacetic trans-
aminase (SGOT), alkaline phosphatase (ALKP), lactate
dehydrogenase (LDH), glucose and lipid profiles that in-
cluded total cholesterol (TC), TG, low density lipoprotein
(LDL), and HDL were also analyzed at screening.
Ethical considerations
The study protocols (with ethical considerations) were
reviewed and approved by research ethics boards at each
participating institution, including the Biomedical Ethics
Board at the University of Manitoba, Comité sectoriel
d’éthique de la recherche en sciences de la santé de
l’Université Laval, and the Institutional Review Board at
the Pennsylvania State University. The trial was regis-
tered at clinicaltrials.gov under the registration number
NCT01351012. Written informed consent was obtained
after an initial interview with each participant. The inter-
view included a full description of the study and a dis-
cussion of the compliance issues and study expectations.
Randomization
Random permutations of the five treatments were created
by the study director at the main site using a random
number generator to ensure that all the subjects received
treatments in a balanced and random order. Sequences
were coded for the purpose of blinding the investigators
and the subjects. Coded sequences were kept in sealed
envelopes at the Winnipeg center and were assigned to
subjects by study coordinators at respective sites as they
joined the study across the three centers.
Study diets
Participants consumed a controlled weight-maintenance,
full-feeding diet with a fixed macronutrient composition
(35% fat, 50% carbohydrate, 15% protein, <200 mg chol-
esterol, 35 to 40 g fiber) for five treatment periods. They
were provided with three meals and two snacks a day
using a seven day rotating menu for the complete dur-
ation of each dietary phase. Each of five treatment phase
extended four 4 weeks and separated by four-week
washout intervals, although ten volunteers took shorter
washout periods of two to four weeks at the PSU site.
Treatment oils were provided as a shake-style beverage,
divided in two equal doses to be consumed at breakfast
and supper. Participants were instructed to consume
one of their meals under supervision on site. Treatment
oils were: 1) conventional canola oil (Canola), 2) high
oleic canola oil (CanolaOleic), 3) 85% high oleic canola
and 15% DHA oil blend (CanolaDHA), 4) 60% flax oil
and 40% safflower oil blend (FlaxSaff), and 5) 25% corn
oil and 75% safflower oil blend (CornSaff). The amount
of treatment oil and/or oil blend was determined based
on the calculated energy requirements of the partici-
pants, with the 3000 Kcal intake targeted to consume
60 g oil per day, and the 1800 and 2400 Kcal groups to
consume 36 and 48 g per day, respectively. Oils were
weighed to the nearest gram and added to the shakes.
Meals and shakes were prepared in the metabolic
kitchen where kitchen staff and clinical coordinators
were blinded to the treatments. Meals and shakes were
provided in cold packs for meals consumed offsite.
These take-out meals were provided to participants at
each center during their daily visit. Weekend meals
and shakes were delivered to the participants’ place of
residence or were dispensed at the feeding site on
Fridays.
A subgroup of participants in Winnipeg prepared their
own meals under the supervision of a trained individual.
This was possible due to personal cultural practices
involving the use of a common kitchen to prepare
community meals. Treatment shakes were prepared at
the RCFFN and delivered to the community every two
to three days.
Subjects were instructed to consume only the pre-
pared meals and to limit their consumption of alcohol
or caffeinated beverages. Diets were planned for every
subject according to their energy requirements and were
nutritionally adequate. Energy requirement was calcu-
lated using the Mifflin-St Jeor equation [30]. During
each study period body weights were monitored, and if
subjects gained or lost weight energy adjustments were
made. Subjects were given a diet that met the Canadian
and United States recommended nutrient intakes. The
nutrient content of the diet was analyzed using FOOD
PROCESSOR (ESHA Research, Salem, Oregon, United
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micronutrient adequacy.
Compliance
Compliance during the trial was determined based on the
remaining amounts of treatment shakes in pre-packaged
food packs intended for off-site consumption, and by a
weekly dietary questionnaire on dietary deviations which
ensured that macro- and micronutrient intakes remained
unchanged. Subjects were instructed to consume at least
one meal on site, further ensuring compliance. These
observations were further confirmed by expected changes
in plasma fatty acid profiles at the end of each dietary
period. For example, a greater than two-fold baseline to
endpoint increase in serum DHA was expected during the
CanolaDHA dietary period.
Intervention
Four oils with different n-9: n-6: n-3 ratios were selected
as the intervention; conventional canola oil (6:2:1), high
oleic canola oil (31:6:1), DHA-enriched high oleic canola
oil (6:1:1), and a flax oil and safflower oil blend (1:1:1).
The fatty acid composition varied noticeably among
treatment oils (Table 2), allowing comparison of the effects
of n-3 fatty acids, ALA and DHA, n-6 fatty acid, LA, and
n-9 fatty acid, oleic acid.
Comparison dietary fat blend
An oil blend of corn (25%) and safflower (75%) with n-9:
n-6: n-3 ratio of 6:25:0.1 was used as the comparison
instead of a high saturated fat blend. Since the effects of
saturated fat have been well established it was deemed
unnecessary to include it as a control. Moreover, we
previously examined the effects of high oleic canola and
flax oil compared to a diet high in saturated fat [23,31].
Additionally n-6 fatty acids, which are abundant in the
comparison oil blend, are considered essential and healthy,
however the concept of the n-6 to n-3 ratio and the effects
on inflammation merits re-examination [13,16]. Using n-6
rich oil enabled us to investigate these concepts.
Outcome measures
Endothelial function was identified as the primary end-
point based on our rationale of evaluating emerging CVD
risk factors beyond traditional lipid biomarkers for CVD.
Secondary endpoints and laboratory analyses are presented
in “List of secondary endpoints analyzed in the COMIT
study” section. All centers followed identical procedures on
all the measurements to minimize the variation. The
peripheral arterial tonometry (PAT) technique was utilized
to measure endothelial function. By using an Endo-PAT
device (Itamar Medical, Caesarea, Israel), this technique
measures the reactive hyperemia which is significantly
correlated with endothelium-dependent vasodilatation [32].
Endothelial function testing was carried out after a 12 hour
fast in the morning before breakfast at beginning and end
of each phase. Scheduling pre-menopausal women for test-
ing within the first seven days of their cycle was attempted
to avoid the impact of hormonal fluctuations on the endo-
thelial function test. Dual energy x-ray absorptiometry
(DEXA) scanning and blood pressure recording using a
digital blood pressure monitor were completed at beginning
and end of each treatment. Blood pressure was recorded
three times and the mean value used for data analysis.
Waist circumference also was taken at the beginning and
Table 2 Fatty acid composition of dietary oils (%)
a
Fatty acids Canola CanolaOleic CanolaDHA
(85:15)
FlaxSaff
(60:40)
CornSaff
(25:75)
c4:0 00 00 0
c6:0 00 00 0
c8:0 00 00 0
c10:0 00 00 0
c12:0 0.09 0.06 0.07 0 0
c14:0 0.07 0.07 0.78 0 0.01
c16:0 4.06 3.66 5.25 4.90 5.86
c17:0 0.07 0.09 0.17 0 0.02
c18:0 1.83 1.83 1.70 3.17 1.90
c20:0 0.65 0.65 0.57 0 0.11
C22:0 0.31 0.31 0.30 0 0
c24:0 0.18 0.18 0.15 0 0
Total SFA 7.26 6.85 8.99 8.07 7.90
c14:1 0 0 0.01 0 0
c16:1 0.25 0.22 0.21 0 0.03
c17:1 0.12 0.20 0.17 0 0
c18:1 58.61 71.47 63.25 17.86 17.60
c20:1 1.22 1.20 1.03 0 0.03
c22:1 0.05 0.07 0.06 0 0
Total MUFA 60.25 73.16 64.73 17.86 17.66
c18:2 n-6 19.54 14.74 12.74 37.47 69.34
c18:3 n-3 9.76 2.30 1.96 31.98 0.29
c20:4 n-6 0 0 0.06 0 0
c20:5 n-3 0 0 0.15 0 0
c22:5 n-3 0 0 2.36 0 0
c22:6 n-3 0 0 5.80 0 0
Total PUFA 29.30 17.04 23.07 69.45 69.63
Total n-6
PUFA
19.54 14.74 12.80 37.47 69.34
Total n-3
PUFA
9.76 2.30 10.27 31.98 0.29
aThe values are % of total fatty acids. The daily 3000 kcal diet block contained
60 g of treatment oil. Canola, conventional canola oil; CanolaOleic, high oleic
canola oil; CanolaDHA, high oleic canola and DHA oil blend; FlaxSaff, flax and
safflower oil blend; CornSaff, corn and safflower oil blend; SFA, saturated fatty
acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids.
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collected on days 1, 2, 29 and 30 in both EDTA or heparin
coated tubes. Blood samples obtained on days 1 and 2 were
used to determine baseline values for study endpoints,
whereas blood samples obtained on the two last days were
used for the endpoint values. Blood was centrifuged for
20 minutes at 520×g to separate either serum or plasma
depending on the requirement of the analysis. Aliquots
of plasma and sera were stored at −80°C until analysis.
Deuterium oxide water was administered on day 29
(0.7 g× kg body water) to track ALA interconversion
to longer chain n-3 PUFA.
List of secondary endpoints analyzed in the COMIT
study
Secondary endpoints
● Cholesterol
● LDL
● HDL
● Triglycerides
● Blood glucose
● Apolipoprotein AI
● Apolipoprotein B
● CRP
● IL-6
● E-selectin
● ICAM-1
● VCAM-1
● Body fat%
● Lean mass
● Fat mass
● Android to gynecoid ratio
● Conversion of ALA to EPA and DHA
● Fatty acid ethanolamine metabolites of oleic acid
● FADS and ELOVL genetic variant (SNP) analyses
● Lipoprotein particle size
● Lipoprotein cholesterol ester composition
● Body weight
● Waist circumference
● Blood pressure
LDL, low density lipoprotein; HDL, high density lipo-
protein; CRP, C-reactive protein; IL-6, interleukin-6;
ICAM-1, intercellular adhesion molecule-1; VCAM-1,
vascular cell adhesion molecule-1; ALA, α-linolenic acid;
EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid;
FADS, fatty acid desaturase; ELOVL, elongases of
very long chain fatty acids; SNP, single nucleotide
polymorphism.
Aliquots of 1 mm plasma EDTA samples obtained from
all participants on days 29 and 30 of each phase were
assembled at RCFFN for total plasma fatty acid profile
analyses. Given the double-blinded crossover design,
compliance was assessed by total plasma fatty acid
concentrations across the three clinical sites and all
five phases. Plasma fatty acids were extracted by the
classic Folch method using chloroform-methanol (2:1,
volume to volume (v/v)) [33] containing 0.01% butylated
hydroxytoluene (Sigma-Aldrich, Oakville, Ontario, Canada),
followed by methylation with methanolic HCl. Fatty acid
methyl esters were then analyzed using an Agilent 6890
N gas chromatograph equipped with a flame ionization
detector (Agilent Technologies, Mississauga, Ontario,
Canada). During the extraction and methylation, hepta-
decanoic acid (C17:0) as an internal standard (Sigma-
Aldrich, Oakville, Ontario, Canada). Known fatty acid
standards (GLC-461, NuChek Prep, Inc. Elysian, Minnesota,
United States) were used to identify the individual fatty
acids in plasma samples. The level of each fatty acid was
then calculated according to the corresponding peak area
relative to the total area of total interested fatty acids, and
considered as a percentage of the total fatty acids.
Data management and statistical analysis
A sample size of 40 subjects per each of the three cen-
ters (120 in total) was determined based on endothelial
function as the primary outcome. Endothelial function
was intended to be assessed by flow mediated dilata-
tion (FMD) The anticipated difference in means was
20% and the standard deviation was 1.35 [34]. Afore-
mentioned sample size was sufficient to detect this
difference with a power of 0.8 at a significance of 0.05.
Endothelial function is a continuous variable which
measures endothelium-dependent vasodilatation. Just
before the beginning of the trial, it was decided to use
the Endo-PAT technique for the measurement of the
endothelial function, and a new sample size calculation
was not made since reactive hyperemia index (RHI)
measured by the Endo-PAT technique is significantly
correlated with FMD [35] and has a similar variability
[36]. We hypothesized that the favorable lipid changes
associated with our proposed dietary interventions
would improve endothelial function short-term. One
hundred and seventy subjects were recruited with the
anticipation of approximately a 20% dropout rate,
based on our prior experience and considering the
long-term commitment needed for the trial. Data from
all centers were uploaded to a secure file storage sys-
tem and specific centers were selected for analysis
based on their expertise. Data were manually checked
for accuracy. A per protocol approach with a mixed
model analysis was decided as appropriate for data ana-
lysis utilizing SAS version 9.2. Kolmogorov-Smirnov (SAS
version 9.2) or Cramer-von Mises (SAS version 9.2)
tests and histograms were used to test the Gaussian
nature of the variables and log transformation was
used if necessary.
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Recruitment, screening, enrollment and retention
From the methodologies used to recruit participants
(Table 1), the most successful recruitment strategy at the
Winnipeg center was direct mailings in selected neighbor-
hoods. Other centers used University email list-serves to
recruit participants. Figure 1 presents the flow of partici-
pants through the study. After the initial contact, 63% of
volunteers were screened for clinical assessment. Only
24% of the volunteers who underwent clinical assessment
were eligible for the study. A total of 170 men and women
were randomized, which represents 15% of the total num-
ber who underwent primary screening. The enrollment
rate was 17%, 18% and 12% for the Winnipeg, Québec
City and University Park centers, respectively.
As shown in Figure 1, Winnipeg had the highest num-
ber of participants (n =69), while University Park had
the fewest (n =43). The dropout rates in the centers
were 22%, 21%, and 30% for Winnipeg, Québec City and
University Park, respectively. The overall dropout rate
was 23.5%. The effect of the dropouts on the study was
minimal because 77.5% of the dropouts occurred within
the first two phases of the study. Moreover, baseline
characteristics of the dropouts and the completers did
not differ significantly (data not shown). Challenges in
retaining participants were expected given the nine-month
duration of the trial and participant study requirements
(frequent visits to the centers, as well as the full-feeding
protocol). As presented in Figure 1, health issues, moving
out of town, level of commitment and job issues were
the major factors behind cessation in the Winnipeg and
Québec City centers. Food issues and academic or work
i s s u e sw e r et h em a j o rr e a s o n sf o rt h eU n i v e r s i t yP a r k
center.
Participant characteristics
Participants were randomized to dietary treatments from
September 2010 through to March 2012. Participants
were classified as having metabolic syndrome as defined
by IDF (Table 3). Winnipeg had the highest percentage
of participants with metabolic syndrome (56%), followed
by University Park (43%) and Québec City (39%). Over-
all, 47% of participants were characterized as having
metabolic syndrome. Although almost 50% of the partic-
ipants had metabolic syndrome, their 10-year coronary
heart disease risk score was less than 4% as determined
by Framingham risk score calculation (data not shown).
Baseline characteristics of participants from the different
centers and the entire cohort are presented in Table 4.
Post-treatment fatty acid profiles
Total plasma fatty acid profiles of the completers of all
five phases are summarized in Table 5. All fatty acid
concentrations were calculated as percentage values of
total identified fatty acids measured. As DHA was part
of the dietary treatment, post-treatment plasma DHA
values were used to evaluate the overall compliance of
the intervention study. The observed significant in-
creases in DHA concentration only following the
CanolaDHA treatment indicated good compliance in
all centers. As well as the shift in DHA levels, other
changes also successfully reflected their dietary intake
after the 28-day treatment phases. Briefly, Canola and
CanolaOleic showed the highest level of MUFA contents
(P<0.05), since their oleic acid levels were significantly
higher than other treatments. Two PUFA-rich diets sig-
nificantly elevated PUFA contents compared to the other
three canola-based MUFA diets (P<0.05), due to their
higher levels of linoleic acid. FlaxSaff provided the lowest
level of arachidonic acid (P<0.05), indicating the competi-
tion between n-3 and n-6 synthesis as the FlaxSaff oil
treatment provided the highest level of dietary ALA.
CanolaDHA and FlaxSaff also showed higher levels of
EPA compared to other three treatments (P<0. 05 ). In
general, the ratio of n-6 to n-3 also successfully explained
the corresponding response to n-3 rich and n-6 rich dietary
treatments, indicating good compliance among participants
across the entire study.
Primary and secondary outcome measures
Data analyses of endothelial function and secondary
outcome measures given in “List of secondary endpoints
analyzed in the COMIT study” section are currently being
carried out.
Adverse effects
Adverse effects were monitored using a questionnaire
distributed by study staff on every Friday of each dietary
phase. Additionally, the clinical study staff assessed the
tolerability of the treatment each day when they interacted
with the participants. No adverse effects of any treatment
diets were reported.
Table 3 The number of metabolic syndrome criteria met
by the participants in the COMIT study at each
participating center
a
Winnipeg Québec city University Park Total
One 13.0% 6.5% 0% 7.7%
Two 31.5% 54.4% 56.7% 45.4%
Three 16.7% 26.1% 30.0% 23.1%
Four 33.3% 10.9% 13.3% 20.8%
Five 5.6% 2.2% 0% 3.1%
aBased on International Diabetic Federation defined criteria for metabolic
syndrome; waist circumference (≥94 cm for men and ≥80 cm for women),
triglycerides ≥1.7 mmol/L, high density lipoprotein <1 mmol/L (males) or <1.3
mmol/L (females), blood pressure ≥130 mmHg (systolic) and/or ≥85 mmHg
(diastolic) and glucose ≥ 5.5 mmol/L.
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The recruitment and retention strategies employed resulted
in the successful completion of the required number of
participants. Retention was also high due to the dedication
and commitment of the study volunteers and clinical
coordinators, as well as the success of the social retention
enhancement program. Differences across centers in
demographic characteristics and baseline parameters
were limited to the male to female ratio, body weight,
waist circumference in females, and diastolic blood
pressure. The success rate of participant completion
was numerically close between Winnipeg and Québec
City, with the University Park center having a lower
rate. The major reason for dropouts in Winnipeg and
Québec City were health reasons, while in University Park
it was more related to experimental diet acceptability.
Predictable elevations of specific plasma fatty acids
representing the major dietary fatty acids in the interven-
tion oils were observed as expected. For example, the
three-fold elevation of plasma ALA following the FlaxSaff
dietary phase compared to the CornSaff dietary phase
demonstrated the ability of flax oil-enriched shakes to
raise serum ALA levels. Similarly, the 1.3-fold elevation of
oleic acid after the CanolaOleic treatment compared to
CornSaff treatment is consistent with its high oleic acid
content. Significantly higher eicosapentaenoic acid (EPA)
levels in Canola and FlaxSaff compared to other treat-
ments are evidence for the metabolic conversion of ALA
to EPA. The significant elevation of EPA in CanolaDHA
compared to other treatments (except FlaxSaff) could
probably be due to the higher EPA content in the algal
sourced DHA that was used in this study. However DHA
might convert back to EPA in CanolaDHA, which can be
further confirmed by the stable isotope-trafficking assays
in this study [37,38]. Similarly, the more than two-fold ele-
vation of DHA after the CanolaDHA treatment, compared
to other treatments, is not surprising and is in line with
previous reports [39-41]. Lack of a DHA raising effect of
FlaxSaff treatment agrees with prior work demonstrating
low efficiency of conversion of ALA to DHA [31]. Re-
markable consistency was observed in compliance among
participants as depicted here by predictable shifts in their
fatty acid profile at the end of each dietary period,
highlighting the successful completion of this long-term
full-feeding clinical trial.
Multicenter randomized controlled clinical trials exist
as the gold standard for evidence-based research [42].
The multicenter nature of the trial ensured the robustness
of results across different centers. The iso-caloric, weight-
maintaining, full-feeding regimen eliminated the effect of
variable habitual, background diets on study outcomes.
Caloric excess or restriction can potentially affect blood
lipids, and even body composition and body weight loss
can affect endothelial function [27], hence requiring stan-
dardized study conditions to prevent weight change. Study
treatments oils were blended at the RCFFN and shipped
to participating centers, removing an important source
of variation. Sample analysis for specific endpoints was
completed for all samples at the center designated for a
particular analysis, in order to remove the effect of inter-
laboratory variation. Clinical measurement protocols, par-
ticularly for endothelial function testing, were harmonized
across centers by training personnel from the University
Park center staff. The crossover design eliminated the
Table 4 Baseline characteristics of participants at each participating center
Winnipeg Québec city University Park Total P value
a
Male 16 29 15 60
Female 38 17 15 70 0.003
BMI (kg/m
2) 29.7± 5.0 30.0±4.3 29.7±3.3 29.8± 4.4 0.928
Age (years) 43.9±15.8 49.9±14.2 45.9±9.6 46.5±14.2 0.105
Total cholesterol (mmol/L) 5.4 ±1.1 5.4±1.0 5.1±0.9 5.3±1.1 0.371
HDL (mmol/L) female 1.3 ±0.1 1.4±0.1 1.3±0.1 1.3±0.1 0.413
male 1.1 ±0.1 1.1±0.1 1.1±0.1 1.1±0.1 0.906
LDL (mmol/L) 3.4 ±1.0 3.4±0.9 3.2±0.9 3.4±0.9 0.572
Triglycerides (mmol/L) 1.6 ±0.9 1.8±0.8 1.5±0.9 1.7±0.9 0.338
Glucose (mmol/l) 5.4 ±1.7 5.3±0.6 5.3±0.5 5.4±1.1 0.788
Body weight (kg) 80.7±15.9 85.8±15.3 89.9±15.7 84.7±15.9 0.042
Waist (cm) female 90.6±11.9 97.4±10.3 98.5±9.9 93.4±11.6 0.033
male 103.4± 13.8 106.9± 8.7 106.5±6.5 105.8±9.9 0.508
SBP (mmHg) 122.4± 20.3 119.8±14.2 118.5±12.4 120.6± 16.7 0.548
DBP (mmHg) 81.2±12.4 70.5±10.5 79.7±7.40 77.0±11.8 <0.001
aAnalysis of variance was used to analyze between-group differences in continuous variables. For categorical variables, Fisher’s exact test or chi square test was
used. BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein; SBP, systolic blood pressure; DBP, diastolic blood pressure.
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and reduced the required sample size. Endothelial func-
tion was found to be significantly changed in studies with
a crossover or a parallel design over a period of four weeks
following dietary intervention, indicating that the study
design and the duration of the current study is appropriate
for detecting changes in endothelial function [43,44].
Moreover, an acute study that measured endothelial
function by FMD four hours after a high-fat meal sup-
plemented with either 25 g olive oil or 40 g of shelled
walnut in hypercholesterolemic subjects [34] also showed
significant changes. FMD [45] and Endo-PAT techniques
[46] are both dependent on nitric oxide mediated vaso-
dilatation which is affected by both short- and long-term
changes in endothelial function. Even though the measure
of percent change in endothelial function has no clinical
relevance as yet, a lower range of endothelial function
(lower two tertiles) as measured by FMD, is associated
with enhanced risk of future cardiovascular events [47].
The final sample size of 130 allowed us to detect a dif-
ference of 9.4% or greater in the RHI, which is a measure
of the endothelial function, and a 10% difference of
LDL-C with a power of 0.8 at a significance of 0.05.
Diets were designed to address contemporary nutrition
questions. Although MUFA generally decreases TC and
LDL-C, the efficacy is considered lesser than PUFA
[48,49]. However, the relative benefits of individual
unsaturated fatty acid classes are increasingly being chal-
lenged; this study was designed to resolve some of these
issues.
Table 5 Plasma fatty acid profile of participants at the end of each dietary phase in 130 participants (g/100 g)
a
Canola CanolaOleic CanolaDHA FlaxSaff CornSaff
c14:0 0.71± 0.04 0.74±0.04 0.71±0.04 0.72±0.04 0.68±0.04
c14:1 0.12± 0.02 0.08±0.02 0.09±0.02 0.08±0.02 0.07±0.02
c16:0 27.04± 0.20
a 27.40±0.20
a 28.10±0.20
b 27.41± 0.20
a 27.35±0.20
a
c16:1 1.14± 0.08 1.10±0.08 0.94±0.08 1.30±0.08 1.13±0.75
c18:0 11.83± 0.10
a 11.79±0.10
a 12.28±0.10
b 12.51±0.10
c 12.34±0.10
bc
c18:1 14.90± 0.19
a 15.52± 0.19
b 13.36± 0.19
c 12.10± 0.18
d 11.62±0.18
d
c18:2 n-6 22.00± 0.23
a 21.52±0.23
a 18.68±0.23
b 25.13±0.23
c 25.93±0.23
d
c18:3 n-6 0.17± 0.07 0.18±0.07 0.23±0.07 0.12±0.07 0.17±0.07
c18:3 n-3 0.79±0.03
a 0.63± 0.03
b 0.57±0.03
bc 1.61±0.03
c 0.49± 0.03
d
c20:0 0.50±0.02
a 0.48±0.02
ab 0.49± 0.02
a 0.41± 0.02
b 0.46±0.02
ab
c20:1 0.32±0.02
a 0.32± 0.02
a 0.27±0.02
ab 0.18±0.02
c 0.23± 0.02
bc
c20:2 n-6 0.35±0.03
a 0.31±0.03
ab 0.24± 0.03
b 0.32±0.03
ab 0.37± 0.03
a
c20:3 n-6 2.45±0.07
ab 2.53± 0.07
b 1.79±0.07
c 1.86±0.07
c 2.28± 0.07
a
c20:4 n-6 9.28±0.15
a 9.67± 0.15
b 9.70± 0.15
b 8.27±0.15
c 9.59±0.15
ab
c20:5 n-3 1.09±0.04
a 0.86± 0.04
b 1.53±0.04
c 1.45±0.04
c 0.49± 0.04
d
c22:0 0.94±0.03
ab 0.90±0.03
ab 1.00± 0.03
a 0.90± 0.03
b 0.93± 0.03
b
c22:4 n-6 0.43± 0.08 0.29±0.08 0.25±0.08 0.22±0.08 0.39±0.08
c22:5 n-3 0.81±0.03
a 0.72± 0.03
b 0.34±0.03
c 0.97± 0.03
d 0.62±0.03
e
c22:6 n-3 2.84±0.09
a 2.79± 0.09
a 7.21± 0.10
b 2.59± 0.09
a 2.66± 0.09
a
c24:0 0.72±0.03
a 0.65± 0.03
b 0.74± 0.03
a 0.74± 0.03
a 0.73± 0.03
a
c24:1 1.56±0.05
a 1.49±0.05
ab 1.55± 0.05
a 1.38± 0.05
b 1.44±0.05
ab
Total SFA 41.74± 0.19
a 41.92± 0.19
ab 43.28± 0.19
c 42.71±0.19
cd 42.51± 0.19
bd
Total MUFA 18.05± 0.22
a 18.50±0.22
a 16.20±0.22
b 14.78±0.22
c 14.49±0.22
c
Total PUFA 40.21± 0.22
a 39.54± 0.22
b 40.47±0.22
a 42.57±0.22
c 43.04±0.22
c
Total n-6 PUFA 34.67± 0.23
a 34.46±0.23
a 30.92±0.23
b 35.92±0.23
c 38.79±0.23
d
Total n-3 PUFA 5.53±0.10
a 5.03± 0.10
b 9.62±0.11
c 6.64± 0.10
d 4.24±0.10
e
n-6:n-3 6.55±0.13
a 7.18± 0.14
b 3.32±0.14
c 5.65± 0.13
d 9.41±0.13
e
aThe values are % abundance of each fatty acid to total fatty acids given as least squares mean ±SE for 130 individuals. Total fatty acid values and ratios are
calculated. Mixed-effects repeated-measures analysis of variance with treatment, age, gender and the dietary phase as fixed effect, the last diet (sequence effect)
as a random effect, and the measures for each subject by phases were used for the data analysis. Canola, conventional canola oil; CanolaOleic, high oleic canola
oil; CanolaDHA, high oleic canola and DHA oil blend; FlaxSaff, flax and safflower oil blend; CornSaff, corn and safflower oil blend; SFA, saturated fatty acids; MUFA,
monounsaturated fatty acids; PUFA, polyunsaturated fatty acids.
abcdeMean values with different superscript letters across rows denote significant differences
at P <0.05.
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will link the changes in surrogate cardiovascular bio-
markers such as blood lipids and glucose, inflammatory
biomarkers and hormones, to clinical endpoints such as
endothelial function and body fat composition. The
mechanistic studies, including lipid trafficking, apolipo-
proteins, lipoprotein particle size, and reverse cholesterol
transport, will assist in clarifying the relationship between
the biomarkers and clinical endpoints. Finally, results will
be evaluated from the perspective of genetic variation,
assessed through single nucleotide polymorphisms among
individuals to assess why biomarker responses vary as a
function of diet treatments.
The study possesses certain limitations. The disparity
in male: female ratio and the baseline differences in
cholesterol across centers can be considered as confound-
ing treatment effects. However, use of a mixed model
approach in statistical analyses is expected to minimize
this effect. The effect of the preceding diet or the sequence
of treatment is another confounding factor that was antic-
ipated to be minimized by the mixed model approach.
Moreover, differences in bioactives other than fatty acid
composition within the treatment oils might affect clinical
measurements such as endothelial function. The intra-
individual and inter-operator variability in endothelial
function testing might likewise obscure a treatment effect.
Thus, standardization of the test procedure represents an
important factor in maintaining the robustness of endo-
thelial function data [50]. Steps were taken to limit this
variability by controlling the environment and also by
minimizing any additional factors such as the stage in the
menstrual cycle of female participants [51], medication,
and tea or coffee drinking [52]. Additionally, use of the
corn and safflower oil blend as the alternate treatment
would be expected to improve blood lipids and other
parameters [6]. Therefore, it may not be possible to see an
improvement in blood lipids in certain treatments com-
pared to the corn and safflower oil blend treatment.
Conclusions
The successful completion of 130 participants through
the study protocol of this nine-month long, full-feeding,
multicenter study represents a significant achievement.
Recruitment and retention strategies used in this study
were instrumental in achieving this goal. Standardized
protocols and efforts to minimize variation are expected
to lead to findings that will help to fill the gaps in our
knowledge of the metabolism, lipid trafficking, and clinical
efficacy of the major classes of dietary fatty acids.
Trial status
The trial started recruiting volunteers in September 2010
and completed the intervention stage in March 2012.
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